日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A Minimum 3-Year Follow-Up of Nivolumab-Plus-Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the J-ENCORE Study

一项针对日本晚期或转移性肾细胞癌患者的纳武利尤单抗联合伊匹木单抗治疗的至少3年随访研究：J-ENCORE研究的最终分析

期刊:International Journal of Urology
影响因子:2.2
doi:10.1111/iju.70400
Hamamoto, Shuzo; Nozawa, Masahiro; Shirotake, Suguru; Sazuka, Tomokazu; Numakura, Kazuyuki; Mizokami, Atsushi; Kondo, Tsunenori; Naito, Sei; Abe, Takashige; Ohba, Kojiro; Kimura, Go; Nagata, Masayoshi; Onodera, Shunta; Yamaguchi, Katsumi; Uemura, Hirotsugu
肿瘤
肾癌
肿瘤免疫
细胞生物学
发表日期：2026
文献求助 收藏

Outcomes of Nivolumab-Plus-Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J-ENCORE Study

纳武利尤单抗联合伊匹木单抗治疗转移性肾细胞癌的疗效：J-ENCORE 研究的第二次中期分析

期刊:International Journal of Urology
影响因子:2.2
doi:10.1111/iju.70281
Sazuka, Tomokazu; Tatsugami, Katsunori; Shirotake, Suguru; Hamamoto, Shuzo; Nozawa, Masahiro; Numakura, Kazuyuki; Mizokami, Atsushi; Kondo, Tsunenori; Naito, Sei; Abe, Takashige; Ohba, Kojiro; Kimura, Go; Onodera, Shunta; Yamaguchi, Katsumi; Uemura, Hirotsugu
肿瘤
肾癌
肿瘤免疫
细胞生物学
发表日期：2026
文献求助 收藏

Quantitative Visualization of Console Behavior During Robot-Assisted Radical Prostatectomy Using the Da Vinci 5 System: A Case-Based Technical Report

利用达芬奇5系统进行机器人辅助根治性前列腺切除术中控制台行为的定量可视化：基于病例的技术报告

期刊:Cureus Journal of Medical Science
影响因子:1.3
doi:10.7759/cureus.105463
Umezawa, Yuta; Kaneko, Go; Igarashi, Daisuke; Shirotake, Suguru; Oyama, Masafumi
发表日期：2026
文献求助 收藏

First-Line Enfortumab Vedotin Plus Pembrolizumab in Platinum-Ineligible Urothelial Carcinoma: A Three-Case Series

一线恩福妥单抗联合帕博利珠单抗治疗铂类不适宜化疗的尿路上皮癌：三例病例系列研究

期刊:Cureus Journal of Medical Science
影响因子:1.3
doi:10.7759/cureus.104355
Igarashi, Daisuke; Kaneko, Go; Takamatsu, Kimiharu; Shirotake, Suguru; Oyama, Masafumi
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

FloSeal® for Parenchymal Hemostasis in Robot-Assisted Partial Nephrectomy: Technical Description and a Report of Two Cases

FloSeal®在机器人辅助部分肾切除术中用于实质止血：技术描述及两例病例报告

期刊:Cureus Journal of Medical Science
影响因子:1.3
doi:10.7759/cureus.103373
Igarashi, Daisuke; Kaneko, Go; Shirotake, Suguru; Oyama, Masafumi
发表日期：2026
文献求助 收藏

Early detection of myocarditis caused by immune checkpoint inhibitor therapy with nivolumab and ipilimumab for advanced recurrent renal cell carcinoma

早期发现由纳武利尤单抗和伊匹木单抗免疫检查点抑制剂治疗晚期复发性肾细胞癌引起的心肌炎

期刊:Cancer Immunology Immunotherapy
影响因子:5.1
doi:10.1007/s00262-025-03945-0
Todo, Maki; Gatate, Yodo; Nakano, Shintaro; Kaneko, Go; Hagiwara, Masayuki; Takahashi, Takayuki; Umezawa, Yuta; Ueda, Genji; Ishikawa, Shiho; Makino, Yoshinori; Oyama, Masafumi; Shirotake, Suguru
肿瘤
肿瘤免疫
心肌炎
肾癌
心血管
细胞生物学
免疫/内分泌
发表日期：2025
文献求助 收藏

Factors associated with primary resistance to enfortumab vedotin in previously treated patients with metastatic urothelial carcinoma: a multicenter retrospective study

既往接受过治疗的转移性尿路上皮癌患者对恩福妥单抗产生原发性耐药的相关因素：一项多中心回顾性研究

期刊:International Journal of Clinical Oncology
影响因子:2.8
doi:10.1007/s10147-025-02822-1
Ikarashi, Daiki; Hayakawa, Nozomi; Kaneko, Go; Sakura, Yuma; Endo, Yuki; Yamashita, Ryo; Shirotake, Suguru; Kondo, Yukihiro; Kikuchi, Eiji; Obara, Wataru
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Proactive Symptom Monitoring by Pharmacists Using a Cancer Patient Support App in Out-patient Oral Multi-kinase Inhibitor Therapy: Feasibility Study of a Small Patient Population

药剂师使用癌症患者支持应用程序对门诊口服多激酶抑制剂治疗患者进行主动症状监测：小样本患者人群可行性研究

期刊:In Vivo
影响因子:1.8
doi:10.21873/invivo.13847
Todo, Maki; Shirotake, Suguru; Kaneko, G O; Okamoto, Kojun; Sugasawa, Masashi; Nakahira, Mitsuhiko; Ishikawa, Shiho; Wakui, Noriko; Makino, Yoshinori; Saeki, Toshiaki
信号转导
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

A Case of Avelumab-Resistant Upper Urothelial Carcinoma Responding to Pembrolizumab

一例对阿维鲁单抗耐药的上尿路尿路上皮癌对帕博利珠单抗治疗有反应的病例

期刊:Cureus Journal of Medical Science
影响因子:1.3
doi:10.7759/cureus.77170
Yokota, Kotaro; Shirotake, Suguru; Miyama, Yu; Takahashi, Takayuki; Umezawa, Yuta; Hagiwara, Masayuki; Kaneko, Go; Oyama, Masafumi
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Neutrophil to lymphocyte ratio and tumour burden for treatment efficacy stratification in renal cell carcinoma patients receiving nivolumab plus ipilimumab

中性粒细胞与淋巴细胞比值和肿瘤负荷用于评估接受纳武利尤单抗联合伊匹木单抗治疗的肾细胞癌患者的疗效分层

期刊:
影响因子:
doi:10.1016/j.esmorw.2024.100106
Oshima, M; Washino, S; Shirotake, S; Takeshita, H; Inoue, M; Miura, Y; Nakayama, A; Nagamoto, S; Nakayama, T; Izumi, K; Oyama, M; Kawakami, S; Saito, K; Matsuoka, Y; Miyagawa, T
肿瘤
中性粒细胞
肿瘤免疫
肾癌
粒细胞
细胞生物学
发表日期：2025
文献求助 收藏